TransMedics Group (TransMedics Group) Cash And Cash Equivalents : $350.2 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group Cash And Cash Equivalents?

TransMedics Group's quarterly cash and cash equivalents declined from Sep. 2023 ($427.11 Mil) to Dec. 2023 ($394.81 Mil) but then stayed the same from Dec. 2023 ($394.81 Mil) to Mar. 2024 ($350.22 Mil).

TransMedics Group's annual cash and cash equivalents increased from Dec. 2021 ($25.58 Mil) to Dec. 2022 ($201.18 Mil) and increased from Dec. 2022 ($201.18 Mil) to Dec. 2023 ($394.81 Mil).

TransMedics Group Cash And Cash Equivalents Historical Data

The historical data trend for TransMedics Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Cash And Cash Equivalents Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

20.09

24.58

25.58

201.18

394.81

TransMedics Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															195.38	582.21	427.11	394.81	350.22

TransMedics Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

TransMedics Group (NAS:TMDX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

TransMedics Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group (TransMedics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

8T8:Germany TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.

Executives

Tamer I Khayal	officer: Chief Commercial Officer	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost	officer: VP of US Regulatory & FDA Rel.	2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein	director, officer: President & CEO	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon	officer: Chief Financial Officer	200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill	director	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile	director	200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey	officer: VP of Operations	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme	officer: VP, Clinical Affairs	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr	director
Rakesh P. Godhani	officer: Chief Digital Officer	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan	officer: VP of Quality & Engineering	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810